^
    Back
    Association details:
    Biomarker:TNFRSF8 expression
    Cancer:Peripheral T-cell Lymphoma
    Drug:TEQ102 (Microtubule inhibitor, CD30-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2022
    Title:

    4229 Tub-010, a Novel Antibody-Drug-Conjugate with Reduced Nonspecific Toxicity Profile Based on Tub-Tag Technology Widens the Therapeutic Window for the Treatment of CD30+ Malignancies

    Published date:
    11/03/2022
    Excerpt:
    TUB-010 showed similar in vitro cytotoxic efficacy as well as similar bystander activity compared to BV on established cancer cell lines from cHL, PTCL and CTCL patients with various levels of CD30 expression...TUB-010 is a promising, novel and potential best-in-class CD30-ADC which can deliver the cytotoxic payload to CD30+ malignancies with higher precision...
    DOI:
    https://doi.org/10.1182/blood-2022-158681